Rising Diabetes Prevalence Fuels Growth In The Glycomic Therapeutics Market: A Significant Driver Propelling The Glycomic Therapeutics Market In 2025

The Glycomic Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Glycomic Therapeutics Market Size and Projected Growth Rate?
In recent times, the market size for glycomic therapeutics has experienced swift expansion. It is projected to escalate from $164.71 billion in 2024 to an impressive $190.03 billion in 2025, indicating a compound annual growth rate (CAGR) of 15.4%. The expansion experienced in the historic period is linked to factors such as heightened understanding of glycan's importance, an uptick in chronic illnesses, the development of drugs for rare diseases, and partnerships in studies related to glycomics.

The market for glycomic therapeutics is predicted to witness a significant expansion in the upcoming years. By 2029, it is projected to reach a valuation of $361.09 billion with a compound annual growth rate (CAGR) of 17.4%. The anticipated growth during the forecast tenure can be credited to the growing understanding of glycan biology, the use of precision medicine, increasing interest in immunotherapy, higher funding for researching rare diseases, and the rise of glycan biomarkers. The forecast period will also see key trends such as the broadening use of glycomic applications in cancer treatment, the enhancement of therapeutic proteins through glycoengineering, the integration of glycomics in immuno-oncology, and application of glycomics in rare and genetic conditions, along with regulatory factors impacting glycomic drugs.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11894

What Are the Major Segments in the Glycomic Therapeutics Market?
The glycomic therapeutics market covered in this report is segmented -

1) By Class: Isolated, Synthetic
2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures
3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action
4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher's Disease, Mps-1 And IV, Cancer, Alzheimer's Disease, Influenza Type A And B, Other Indications

Subsegments:
1) By Isolated: Natural Glycans, Glycan Derivatives, Glycoproteins
2) By Synthetic: Chemically Synthesized Glycans, Recombinant Glycans, Glycopeptides

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11894&type=smp

What Are The Driving Glycomic Therapeutics Market Evolution?
The rise in diabetes cases is likely to fuel the expansion of the glycomic therapeutics market. Diabetes, a long-term health condition, impacts the body's capacity to control blood sugar (glucose) levels. Changes in glycans have been noted in diabetes patients, which could lead to insulin resistance and other metabolic issues. Specific patterns of glycans act as biomarkers for the diagnosis of diabetes, its progression prediction, and monitoring of treatment reactions. For example, the IDF Diabetes Atlas, a Belgium-based comprehensive resource on diabetes prevalence, projected in March 2022 that the global occurrence of diabetes will surge from 643 million in 2030 to 783 million by 2045, indicating an addition of 140 million cases. Hence, the rise in diabetes prevalence is propelling the advancement of the glycomic therapeutics market.

Which Firms Dominate The Glycomic Therapeutics Market Segments?
Major companies operating in the glycomic therapeutics market include F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., GlycoMar Limited

What Trends Are Expected to Dominate the Glycomic Therapeutics Market in the Next 5 Years?
The emergence of product innovation is a growing trend in the glycomic therapeutics market. Leading firms within this sector are concentrating on the creation of unique, technologically advanced solutions to solidify their market presence. For example, in April 2022, the Indian pharmaceutical firm, Glenmark Pharmaceuticals Limited, unveiled a new fixed-dose combination (FDC) of a DPP4 inhibitor, Teneligliptin, and Pioglitazone. This innovative combination is designed to enhance glycemic control and decrease insulin resistance among patients with type 2 diabetes. The firm is proactively exploring more such advanced treatments.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Which Is The Largest Region In The Glycomic Therapeutics Market?
North America was the largest region in the glycomic therapeutics in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Glycomic Therapeutics Market?
2. What is the CAGR expected in the Glycomic Therapeutics Market?
3. What Are the Key Innovations Transforming the Glycomic Therapeutics Industry?
4. Which Region Is Leading the Glycomic Therapeutics Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.